CMS Proposes Faster Drug Prior Authorization For Some Health Plans

CMS released a proposed rule on April 10, 2026, and it was published in the Federal Register on April 14, 2026. The proposal would extend many prior-authorization interoperability rules to prescription drugs for certain federally regulated health plans. But this is still a proposal, not a final rule, so most patients will not see an immediate change at the pharmacy or in plan paperwork.

If CMS finalizes it, the biggest direct effects would be on Medicare Advantage, Medicaid, CHIP, and Qualified Health Plans sold on the federally facilitated exchanges through HealthCare.gov. CMS also proposes bringing small-group FF-SHOP issuers into the broader interoperability framework. Most employer-sponsored coverage and most off-exchange commercial plans would still not be directly covered.

Why this matters now

Prescription prior authorization can delay treatment even when a medication is eventually approved. In an April 2026 cross-sectional study in JAMA Health Forum, researchers examined 205,896 branded medication dispensations that were initially rejected for prior authorization. Only 35% were processed in 1 day, while 54% were eventually approved. Among the prescriptions that were not processed in 1 day, the median processing time was 6 days. That does not mean every delay caused harm, but it does show that many patients do not get a same-day answer after an initial rejection.

The study also has important limits. It used 2024 pharmacy claims data, focused on branded drugs, and looked at claims that completed the adjudication process, so it does not capture every medication, every insurer, or every patient experience. Still, it offers a useful snapshot of how often a first rejection turns into a delay rather than a quick final answer.

That helps explain why CMS is focusing on this issue now. The American Medical Association‘s 2024 physician survey found that doctors continue to report care delays, treatment disruption, administrative burden, and out-of-pocket costs tied to prior authorization. Those findings reflect physician reports rather than a direct count of patient outcomes, but they add context for why drug prior authorization remains a major access problem.

Who the proposal would cover

Under the proposal, the affected payers would include Medicare Advantage organizations, state Medicaid fee-for-service programs, Medicaid managed care plans, state CHIP fee-for-service programs, CHIP managed care entities, and Qualified Health Plan issuers on the federally facilitated exchanges. CMS also proposes adding small-group FF-SHOP issuers as impacted payers for interoperability requirements.

Just as important, the proposal would not directly apply to most other private coverage. In plain language, that means most employer-sponsored plans, most commercial plans sold outside the federally run Marketplace, and other non-FFE coverage would remain outside this rule unless an insurer voluntarily applies similar policies more broadly.

What could change if CMS finalizes the rule

Electronic prior authorization for drugs could expand. CMS proposes to require impacted payers to support electronic prior authorization for drugs covered under a medical benefit beginning October 1, 2027. Medicaid, CHIP, and federally facilitated Marketplace issuers would also have to support certain pharmacy-benefit electronic standards for drugs, which would bring them closer to the existing Medicare Part D approach.
Some decision timeframes could become shorter or more standardized. For Medicaid and CHIP, the proposal generally ties drug decisions to existing program rules, which can mean 24 hours for some covered outpatient drugs or the same 7-day standard and 72-hour expedited timeframes already used for other items and services. For HealthCare.gov plans on the federally facilitated exchanges, CMS proposes provider notice within 72 hours for standard drug requests and 24 hours for expedited requests.
Some payers would have to give providers a specific denial reason for drugs. CMS proposes this for state Medicaid and CHIP fee-for-service programs, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the federally facilitated exchanges, starting October 1, 2027.
Public reporting could become more useful. CMS proposes annual public reporting of drug prior-authorization metrics, including the list of drugs requiring prior authorization, approval and denial totals and percentages, approvals after appeal, and average and median decision times. For these new drug metrics, public posting would begin in 2028 for the 2027 reporting period, with reporting levels and deadlines varying by payer type.

A reality check by program

Medicare Advantage: this proposal does not start from zero. Medicare Advantage plans already have existing decision timeframes for Part B drugs, and Part D sponsors already have electronic prior authorization requirements and 72-hour standard and 24-hour expedited decision requirements for Part D drugs. That means the biggest changes here are more about alignment, reporting, and technical standards than about creating an entirely new Part D turnaround system.

Medicaid and CHIP: this is where the proposal could feel newer and more noticeable, especially around electronic drug prior authorization, denial explanations to providers, and public reporting. Even here, though, experiences could still vary by state, by fee-for-service versus managed care, and by whether a drug is handled under a medical benefit or a pharmacy benefit.

HealthCare.gov plans on the federally facilitated exchanges: this may be one of the clearest consumer-facing areas of change if the rule is finalized. Current federal claims rules generally allow longer standard decision timeframes for these plans than the proposal would. CMS is now proposing more explicit and faster provider-notice timeframes for drug prior authorization, along with denial-reason and reporting requirements.

What this proposal would not do

The proposal would not ban prior authorization. It would not guarantee approval of a medication request. It would not automatically fix every pharmacy delay in 2026. And it would not cover every kind of insurance in the United States.

Even if finalized, many of the main compliance dates would begin on October 1, 2027, with some reporting requirements starting in 2028. Real-world experiences would still vary by plan, state, benefit design, provider workflow, and the specific drug involved.

What to do now if a medication request is stuck

If a prescription is delayed by prior authorization, start by identifying your plan type: Medicare Advantage, Medicaid, CHIP, a HealthCare.gov plan on a federally facilitated exchange, or something else. That matters because this proposal would not reach every kind of coverage.

Then ask for the specific denial reason, whether the request can be reviewed as urgent, and what the deadline is for an appeal or resubmission. Keep copies of denial letters, portal messages, dates, names, and reference numbers. Ask the prescribing clinician’s office whether more documentation could help and whether there is a covered alternative if the delay is likely to continue.

If the delay is causing rapidly worsening symptoms or feels like an emergency, seek urgent or emergency care right away. Otherwise, contact the prescribing clinician or pharmacist promptly rather than stopping or changing treatment on your own because of an insurance problem.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.